Latest Breaking News On - Industrie biomediche insubri - Page 1 : comparemela.com

TheraVet Reports Its 2022 Half-year Results and Provides an Update on the Development of Its Activities

Regulatory News: TheraVet (ISIN: BE0974387194 ticker: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in pets, today announces its financial

Walloon regionWaals gewestUnited statesFrance generalUnited kingdomBruxelles capitaleArthur rouillMartin hugo willefertIndustrie biomediche insubriNewcap belgiqueVeterinary orthopedic societyWorld veterinary orthopaedic congressFinancial communicationsRegulatory newsUnited kingdom irelandGeneral assembly

TheraVet Provides Its 2022 First Half-year Operational Update

TheraVet Provides Its 2022 First Half-year Operational Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalUnited kingdomBruxelles capitaleWaals gewestMartin olivier bricaudEnrico bastianelliArthur rouillIndustrie biomediche insubriAmbre delvalNewcap belgiqueConference of the veterinary orthopedic societyWorld veterinary orthopaedic congressFinancial communicationsChief executive officerBone surgery

TheraVet Reports Full Year 2021 Financial Results and Confirms Its Ambitious Development and Commercial Plans for 2022

Positive safety and efficacy results for BIOCERA-VET (arthrodesis and canine osteosarcoma) and VISCO-VET (canine osteoarthritis) Initiation of the pivotal European multicentric clinical study

United statesFrance generalUnited kingdomBruxelles capitaleWaals gewestMartin olivier bricaudEnrico bastianelliArthur rouillIndustrie biomediche insubriAmbre delvalNewcap belgiqueFinancial communicationsChief executive officerInitial public offeringInitial publicVeterinary orthopedic conference

TheraVet Reports Full Year 2021 Financial Results and Confirms Its Ambitious Development and Commerc

Positive safety and efficacy results for BIOCERA-VET® (arthrodesis and canine osteosarcoma) and VISCO-VET® (canine osteoarthritis)Initiation of the pivotal European multicentric clinical study evaluating VISCO-VET® in canine osteoarthritisCommercialization of BIOCERA-VET® Bone Surgery and BIOCERA-VET® Osteosarcoma i.

United statesFrance generalUnited kingdomWaals gewestBruxelles capitaleMartin olivier bricaudEnrico bastianelliArthur rouillIndustrie biomediche insubriAmbre delvalNewcap belgiqueFinancial communicationsBone surgeryRegulatory newsChief executive officerInitial public offering